| Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients MB Lustberg, P Balasubramanian, B Miller, A Garcia-Villa, C Deighan, ... Breast Cancer Research 16, 1-15, 2014 | 123 | 2014 |
| Multiparameter analysis, including EMT markers, on negatively enriched blood samples from patients with squamous cell carcinoma of the head and neck P Balasubramanian, JC Lang, KR Jatana, B Miller, E Ozer, M Old, ... Public Library of Science 7 (7), e42048, 2012 | 123 | 2012 |
| On-chip magnetic separation and encapsulation of cells in droplets A Chen, T Byvank, WJ Chang, A Bharde, G Vieira, BL Miller, JJ Chalmers, ... Lab on a Chip 13 (6), 1172-1181, 2013 | 98 | 2013 |
| Isolation and analysis of rare cells in the blood of cancer patients using a negative depletion methodology Y Wu, CJ Deighan, BL Miller, P Balasubramanian, MB Lustberg, ... Methods 64 (2), 169-182, 2013 | 52 | 2013 |
| Assessment of γ-H2AX levels in circulating tumor cells from patients receiving chemotherapy A Garcia-Villa, P Balasubramanian, BL Miller, MB Lustberg, ... Frontiers in Oncology 2, 128, 2012 | 25 | 2012 |
| Atezolizumab for advanced alveolar soft part sarcoma AP Chen, E Sharon, G O’Sullivan-Coyne, N Moore, JC Foster, JS Hu, ... New England Journal of Medicine 389 (10), 911-921, 2023 | 22 | 2023 |
| Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors GOS Coyne, L Wang, J Zlott, L Juwara, JM Covey, JH Beumer, ... Cancer chemotherapy and pharmacology 85, 979-993, 2020 | 17 | 2020 |
| Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]‐Fluorothymidine Positron … R Wesolowski, DG Stover, MB Lustberg, A Shoben, M Zhao, E Mrozek, ... The Oncologist 25 (8), e1158-e1169, 2020 | 16 | 2020 |
| A MagDot-nanoconveyor assay detects and isolates molecular biomarkers KD Mahajan, GB Vieira, G Ruan, BL Miller, MB Lustberg, JJ Chalmers, ... Chemical Engineering Progress 108, 41, 2012 | 14 | 2012 |
| Multiparameter Evaluation of the Heterogeneity of Circulating Tumor Cells Using Integrated RNA In Situ Hybridization and Immunocytochemical Analysis Y Wu, KJJ Park, C Deighan, P Amaya, B Miller, Q Pan, M Zborowski, ... Frontiers in Oncology 6, 234, 2016 | 12 | 2016 |
| Synthesis of polymer nanoparticles via electrohydrodynamic emulsification-mediated self-assembly KH Lee, M Ireland, BL Miller, BE Wyslouzil, JO Winter Journal of Colloid and Interface Science 586, 445-456, 2021 | 9 | 2021 |
| Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors. A Mittra, GH O'Sullivan Coyne, KT Do, SA Piha-Paul, S Kummar, ... Journal of Clinical Oncology 37 (15_suppl), 3067-3067, 2019 | 9 | 2019 |
| A phase I dose-escalation study of ABT-888 (veliparib) in combination with carboplatin in HER2-negative metastatic breast cancer (MBC). S Viswanathan, R Wesolowski, RM Layman, G Alejandra, B Miller, ... Journal of Clinical Oncology 29 (15_suppl), TPS106-TPS106, 2011 | 7 | 2011 |
| Cell Enrichment from human blood through red cell lysis BL Miller, JJ Chalmers, WG Lowrie Methods in Cell Biology 112, 183-192, 2012 | 5 | 2012 |
| Phase I trial of 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) in patients with advanced solid tumors. J Nguyen, GH O'Sullivan Coyne, N Takebe, AR Naqash, J Mukherjee, ... Journal of Clinical Oncology 39 (15_suppl), 3088-3088, 2021 | 3 | 2021 |
| EpCAM-negative cancer–associated circulating cells (CACS) in blood samples of women with triple-negative breast cancer (TNBC). MB Lustberg, P Balasubramanian, B Miller, A Garcia Villa, S Carothers, ... Journal of Clinical Oncology 29 (15_suppl), e11559-e11559, 2011 | 3 | 2011 |
| Abstract CT138: phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes JQ Nguyen, G O'Sullivan Coyne, L Rubinstein, S Kummar, L Juwara, ... Cancer Research 81 (13_Supplement), CT138-CT138, 2021 | 2 | 2021 |
| Tumor genomic analysis for biomarker identification in a phase I trial of the Wee 1 inhibitor adavosertib (AZD1775). AR Naqash, A Mittra, GH O'Sullivan Coyne, L Chen, B Das, S Kummar, ... Journal of Clinical Oncology 38 (15_suppl), 3624-3624, 2020 | 2 | 2020 |
| Abstract CT099: DNA damage response and therapeutic activity following once-daily administration of the Wee 1 inhibitor AZD1775 (adavosertib) A Mittra, GOS Coyne, S Kummar, K Do, A Bruns, L Juwara, R Piekarz, ... Cancer Research 79 (13_Supplement), CT099-CT099, 2019 | 1 | 2019 |
| Trial in progress abstract phase I trial of 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) in patients with advanced solid tumors. MC Monge B, GH O'Sullivan Coyne, R Piekarz, N Takebe, A Bruns, ... Journal of Clinical Oncology 37 (15_suppl), TPS3148-TPS3148, 2019 | 1 | 2019 |
